RhoVac is an immunotherapy company listed on the Spotlight stock market in Sweden, with a 100%-owned subsidiary in Denmark. It is developing a peptide-based immunotherapy, RV001, which aims to train the immune system to specifically target cancer cells with metastatic potential.
RhoVac is developing RV001, a cancer immunotherapy designed to prevent or limit progression to metastatic disease after curative intent therapy, by activating T-cells against cells with metastatic potential. RV001 contains a fragment of the target protein RhoC, which is overexpressed in cells with metastatic potential across a range of cancers. In November, the FDA granted Fast Track Designation for RV001 in prostate cancer. The existing funding should be sufficient to complete the Phase IIb study in prostate cancer ongoing in Europe and the US (full recruitment expected in Q221 with results expected early-2022, subject to potential pandemic headwinds), as well as covering exploratory preclinical studies in other cancers. RhoVac’s strategic aim is to secure a partner for the late-stage development and global launch of RV001 after completion of the Phase IIb study.
Metastatic cancer is the most advanced stage of cancer and is terminal. A large proportion of patients diagnosed with local cancer already have undetectable metastatic cells or micro-metastases that have infiltrated other tissues. Preventing or halting metastasis formation through inhibiting the metastatic cascade or selectively killing cells with metastatic potential could help contribute to a reduction of morbidity and an improved survival.